[{"orgOrder":0,"company":"Arda Therapeutics","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"Targeted Cell Depletion Therapy","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Arda Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Arda Therapeutics \/ Andreessen Horowitz","highestDevelopmentStatusID":"2","companyTruncated":"Arda Therapeutics \/ Andreessen Horowitz"}]

Find Clinical Drug Pipeline Developments & Deals by Arda Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          NextGen Biomed
                          Not Confirmed
                          NextGen Biomed
                          Not Confirmed

                          Details : The proceeds will be used to advance targeted cell depletion therapies for the treatment of chronic diseases.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 09, 2024

                          Lead Product(s) : Targeted Cell Depletion Therapy

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Discovery

                          Sponsor : Andreessen Horowitz

                          Deal Size : $43.0 million

                          Deal Type : Series A Financing

                          blank